CoChat

Directing fratricide within T cell products using an anti-uPAR chimeric antigen receptor to drive the production of potent therapeutic cells

Sarko, Lauren E., Givand, David, Rattin, Brendan, Shepley, Claire, Tommasi, Anna, Attar, Allen, Taylor, Rachel, Kutler, Benjamin, Traynor, Roshini M., Upadhyaya, Anika, Mnuk, Mackenzie, Gehrke, Cavin, Murren, Nathan, Ulland, Tyler K., Capitini, Christian M., Kotanchek, Theresa, Saha, Krishanu · 2026 · Molecular Therapy
Cited by 2

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ymthe.2026.05.029

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 65

  1. Moradi, 2024, Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review, Front. Oncol., 14, 10.3389/fonc.2024.1388475 · DOI
  2. Jing, 2021, Cas9-cleavage sequences in size-reduced plasmids enhance nonviral genome targeting of CARs in primary human T cells, Small Methods, 5, 10.1002/smtd.202100071 · DOI
  3. Tommasi, 2025, Efficient nonviral integration of large transgenes into human T cells using Cas9-CLIPT, Mol. Ther. Methods Clin. Dev., 33, 10.1016/j.omtm.2025.101437 · DOI
  4. Juillerat, 2020, Straightforward generation of ultrapure off-the-shelf allogeneic CAR-T cells, Front. Bioeng. Biotechnol., 8, 678, 10.3389/fbioe.2020.00678 · DOI
  5. Chang, 2025, SEED-Selection enables high-efficiency enrichment of primary T cells edited at multiple loci, Nat. Biotechnol., 43, 2043, 10.1038/s41587-024-02531-6 · DOI
  6. Paul, 2018, Efficient enrichment of gene-modified primary T cells via CCR5-targeted integration of mutant dihydrofolate reductase, Mol. Ther. Methods Clin. Dev., 9, 347, 10.1016/j.omtm.2018.04.002 · DOI
  7. Valton, 2015, A multidrug-resistant engineered CAR T cell for allogeneic combination immunotherapy, Mol. Ther., 23, 1507, 10.1038/mt.2015.104 · DOI
  8. Jonnalagadda, 2013, Engineering human T cells for resistance to methotrexate and mycophenolate mofetil as an in vivo cell selection strategy, PLoS One, 8, 10.1371/journal.pone.0065519 · doi:10.1371/journal.pone.0065519
  9. Liu, 2024, Targeting metabolism to improve CAR-T cells therapeutic efficacy, Chin. Med. J. (Engl.), 137, 909, 10.1097/CM9.0000000000003046 · DOI
  10. Wang, 2011, A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells, Blood, 118, 1255, 10.1182/blood-2011-02-337360 · DOI · Paper page
  11. Bister, 2022, Optimized NGFR-derived hinges for rapid and efficient enrichment and detection of CAR T cells in vitro and in vivo, Mol. Ther. Oncolytics, 26, 120, 10.1016/j.omto.2022.05.012 · DOI
  12. Philip, 2014, A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy, Blood, 124, 1277, 10.1182/blood-2014-01-545020 · DOI · Paper page
  13. Tang, 2023, Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development, Mol. Ther., 31, 3146, 10.1016/j.ymthe.2023.09.021 · DOI · Paper page
  14. Wang, 2021, Bcl-2 enhances chimeric antigen receptor T cell persistence by reducing activation-induced apoptosis, Cancers (Basel), 13, 197, 10.3390/cancers13020197 · DOI
  15. Zhang, 2024, Unlocking apoptotic pathways: Overcoming tumor resistance in CAR-T-cell therapy, Cancer Med., 13, 10.1002/cam4.70283 · DOI
  16. Xia, 2024, Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy, Mol. Cancer, 23, 175, 10.1186/s12943-024-02079-8 · DOI
  17. Borot, 2025, Multiplex base editing to protect from CD33 directed drugs for immune and gene therapy, Nat. Commun., 16, 4899, 10.1038/s41467-025-59713-2 · DOI
  18. Guerrero, 2024, GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency, Nat. Commun., 15, 8658, 10.1038/s41467-024-52666-y · DOI
  19. Kawalekar, 2016, Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells, Immunity, 44, 712, 10.1016/j.immuni.2016.02.023 · DOI · Paper page
  20. Lontos, 2023, Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors, J. Immunother. Cancer, 11, 10.1136/jitc-2022-006522 · DOI
  21. Vormittag, 2018, A guide to manufacturing CAR T cell therapies, Curr. Opin. Biotechnol., 53, 164, 10.1016/j.copbio.2018.01.025 · DOI · Paper page
  22. Soerens, 2023, Functional T cells are capable of supernumerary cell division and longevity, Nature, 614, 762, 10.1038/s41586-022-05626-9 · DOI · Paper page
  23. Vučinić, 2025, Impact of cellular composition and T-cell senescence of mononuclear cell concentrates on the manufacturing process of chimeric antigen receptor (CAR) T-cells, Transfusion, 65, 1650, 10.1111/trf.18354 · DOI
  24. Amor, 2024, Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction, Nat. Aging, 4, 336, 10.1038/s43587-023-00560-5 · DOI · Paper page
  25. Yang, 2023, NKG2D-CAR T cells eliminate senescent cells in aged mice and nonhuman primates, Sci. Transl. Med., 15, 10.1126/scitranslmed.add1951 · DOI · Paper page
  26. Deng, 2024, Targeting senescent cells with NKG2D-CAR T cells, Cell Death Discov., 10, 217, 10.1038/s41420-024-01976-7 · DOI · Paper page
  27. Zhang, 2026, A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy, Cell, 189, 2898, 10.1016/j.cell.2026.03.002 · DOI
  28. Sarko, 2023, Harnessing chimeric antigen receptor (CAR)-T cells as a potential treatment for Alzheimer’s disease, CGTI, 9, 1003, 10.18609/cgti.2023.132 · DOI
  29. Wang, 2019, Basing on uPAR-binding fragment to design chimeric antigen receptors triggers antitumor efficacy against uPAR expressing ovarian cancer cells, Biomed. Pharmacother., 117, 10.1016/j.biopha.2019.109173 · DOI · Paper page
  30. Santi, 2021, The Urokinase Receptor: A Multifunctional Receptor in Cancer Cell Biology. Therapeutic Implications, Int. J. Mol. Sci., 22, 10.3390/ijms22084111 · DOI
  31. Blasi, 2002, uPAR: a versatile signalling orchestrator, Nat. Rev. Mol. Cel Biol., 3, 932, 10.1038/nrm977 · DOI · Paper page
  32. Isakov, 2002, Protein kinase C(theta) in T cell activation, Annu. Rev. Immunol., 20, 761, 10.1146/annurev.immunol.20.100301.064807 · DOI · Paper page
  33. Nykjaer, 1994, Urokinase receptor. An activation antigen in human T lymphocytes, J. Immunol., 152, 505, 10.4049/jimmunol.152.2.505 · DOI · Paper page
  34. Mueller, 2022, Production and characterization of virus-free, CRISPR-CAR T cells capable of inducing solid tumor regression, J. Immunother. Cancer, 10, 10.1136/jitc-2021-004446 · DOI
  35. Cappabianca, 2024, Metabolic priming of GD2 TRAC-CAR T cells during manufacturing promotes memory phenotypes while enhancing persistence, bioRxiv
  36. Shankar, 2025, Virus-free CRISPR knockin of a chimeric antigen receptor into KLRC1 generates potent GD2-specific natural killer cells, Mol. Ther., 33, 1014, 10.1016/j.ymthe.2025.01.024 · DOI
  37. Eyquem, 2017, Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection, Nature, 543, 113, 10.1038/nature21405 · DOI · Paper page
  38. Lazzarotto, 2020, CHANGE-seq reveals genetic and epigenetic effects on CRISPR–Cas9 genome-wide activity, Nat. Biotechnol., 38, 1317, 10.1038/s41587-020-0555-7 · DOI · Paper page
  39. Bozza, 2021, A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells, Sci. Adv., 7, 10.1126/sciadv.abf1333 · DOI · Paper page
  40. An, 2024, Enhancement of the viability of T cells electroporated with DNA via osmotic dampening of the DNA-sensing cGAS-STING pathway, Nat. Biomed. Eng., 8, 149, 10.1038/s41551-023-01073-7 · DOI
  41. Watanabe, 2023, Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies, Mol. Ther., 31, 24, 10.1016/j.ymthe.2022.09.003 · DOI
  42. Weber, 2021, Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling, Science, 372, 10.1126/science.aba1786 · DOI · Paper page
  43. Quax, 1998, Binding of human Urokinase-type plasminogen activator to its receptor, Arterioscler. Thromb. Vasc. Biol., 18, 693, 10.1161/01.ATV.18.5.693 · doi:10.1161/01.atv.18.5.693
  44. Estreicher, 1989, Characterization of the cellular binding site for the urokinase-type plasminogen activator, J. Biol. Chem., 264, 1180, 10.1016/S0021-9258(19)85069-X · DOI · Paper page
  45. Kouro, 2022, Exhaustion of CAR T cells: potential causes and solutions, J. Transl. Med., 20, 239, 10.1186/s12967-022-03442-3 · DOI
  46. Avery, 2018, Tim-3 co-stimulation promotes short-lived effector T cells, restricts memory precursors, and is dispensable for T cell exhaustion, Proc. Natl. Acad. Sci. USA, 115, 2455, 10.1073/pnas.1712107115 · DOI · Paper page
  47. Ferris, 2014, Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion, J. Immunol., 193, 1525, 10.4049/jimmunol.1400557 · DOI · Paper page
  48. Hanley, 2019, Fresh versus frozen: Effects of cryopreservation on CAR T cells, Mol. Ther., 27, 1213, 10.1016/j.ymthe.2019.06.001 · DOI
  49. Machy, 2023, Biology of GD2 ganglioside: implications for cancer immunotherapy, Front. Pharmacol., 14, 10.3389/fphar.2023.1249929 · DOI
  50. Nazha, 2020, Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy, Front. Oncol., 10, 1000, 10.3389/fonc.2020.01000 · DOI · Paper page
  51. Pluskota, 2003, Convergence of the adhesive and fibrinolytic systems: recognition of urokinase by integrin alpha Mbeta 2 as well as by the urokinase receptor regulates cell adhesion and migration, Blood, 101, 1582, 10.1182/blood-2002-06-1842 · doi:10.1182/blood-2002-06-1842
  52. Gómez-Melero, 2025, Tandem CAR-T cell therapy: recent advances and current challenges, Front. Immunol., 16, 10.3389/fimmu.2025.1546172 · DOI
  53. Weinkove, 2019, Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations, Clin. Transl. Immunol., 8, 10.1002/cti2.1049 · DOI · Paper page
  54. Saura-Esteller, 2022, Gamma delta T-cell based cancer immunotherapy: Past-present-future, Front. Immunol., 13, 10.3389/fimmu.2022.915837 · DOI · Paper page
  55. Hu, 2023, γδ T cells: origin and fate, subsets, diseases and immunotherapy, Signal. Transduct. Target. Ther., 8, 434, 10.1038/s41392-023-01653-8 · DOI · Paper page
  56. Rassek, 2025, New player in CAR-T manufacture field: comparison of umbilical cord to peripheral blood strategies, Front. Immunol., 16, 10.3389/fimmu.2025.1561174 · DOI
  57. Ebrahimiyan, 2022, Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages, Int. Immunopharmacol., 106, 10.1016/j.intimp.2022.108587 · DOI
  58. Chang, 1996, Mice lacking the MHC class II transactivator (CIITA) show tissue-specific impairment of MHC class II expression, Immunity, 4, 167, 10.1016/S1074-7613(00)80681-0 · DOI · Paper page
  59. Hu, 2024, Hypoimmune islets achieve insulin independence after allogeneic transplantation in a fully immunocompetent non-human primate, Cell Stem Cell, 31, 334, 10.1016/j.stem.2024.02.001 · DOI · Paper page
  60. Sterner, 2021, CAR-T cell therapy: current limitations and potential strategies, Blood Cancer J., 11, 69, 10.1038/s41408-021-00459-7 · DOI · Paper page
  61. Shahzadi, 2024, Artificial intelligence for chimeric antigen receptor-based therapies: a comprehensive review of current applications and future perspectives, Ther. Adv. Vaccin. Immunother., 12
  62. Lebrun, 2025, Accelerating CAR-T manufacturing: Establishing an AI and automation-driven analytical development platform, Cytotherapy, 27, 10.1016/j.jcyt.2025.03.249 · doi:10.1016/j.jcyt.2025.03.249
  63. Daniels, 2022, Decoding CAR T cell phenotype using combinatorial signaling motif libraries and machine learning, Science, 378, 1194, 10.1126/science.abq0225 · DOI
  64. Sin, 2024, A high-density microfluidic bioreactor for the automated manufacturing of CAR T cells, Nat. Biomed. Eng., 8, 1571, 10.1038/s41551-024-01219-1 · DOI
  65. Stringer, 2021, Cellpose: a generalist algorithm for cellular segmentation, Nat. Methods, 18, 100, 10.1038/s41592-020-01018-x · DOI · Paper page

Cited by

See all 2

Metadata

Authors
Sarko, L. E., Givand, D., Rattin, B., Shepley, C., Tommasi, A., Attar, A., Taylor, R., Kutler, B., Traynor, R. M., Upadhyaya, A., Mnuk, M., Gehrke, C., Murren, N., Ulland, T. K., Capitini, C. M., Kotanchek, T., & Saha, K.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2026-09
Volume
34
Issue
9
Pages
5190-5206
ISSN
1525-0016
Cited by
2
References
9
Language
en
Licence
Funders
  • National Science Foundation
  • National Cancer Institute (R01 CA278051)
  • National Institutes of Health
  • Wisconsin Alumni Research Foundation Inc
  • Midwest Athletes Against Childhood Cancer
  • Saint Baldricks Foundation
  • University of Wisconsin-Madison
  • Grainger Institute for Engineering, University of Wisconsin-Madison

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Directing fratricide within T cell products using an anti-uPAR chimeric antigen receptor to drive the production of potent therapeutic cells. https://app.cochat.ai/papers/10.1016/j.ymthe.2026.05.029
The paper
Sarko, L. E., Givand, D., Rattin, B., Shepley, C., Tommasi, A., Attar, A., Taylor, R., Kutler, B., Traynor, R. M., Upadhyaya, A., Mnuk, M., Gehrke, C., Murren, N., Ulland, T. K., Capitini, C. M., Kotanchek, T., & Saha, K. (2026). Directing fratricide within T cell products using an anti-uPAR chimeric antigen receptor to drive the production of potent therapeutic cells. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2026.05.029

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.